Showing all 4 results
CILNIDIPINE & TELMISARTAN TABLETS
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Bilayer or Co-Processed Tablet, packed exclusively in secure, high-barrier Alu-Alu blister strips to ensure the stability of the moisture-sensitive Telmisartan and light-sensitive Cilnidipine.
Active Ingredient Strength Primary Clinical Function Telmisartan USP/Ph.Eur. 40 mg The Hormonal Stabilizer: Blocks the RAAS system to provide 24-hour systemic pressure control and metabolic benefits (PPAR-gamma activation). Cilnidipine USP/Ph.Eur. 10 mg The Vascular Relaxant: Provides immediate N-type and L-type calcium channel blockade to lower peripheral resistance without edema. Excipients Meglumine / Sorbitol / Sodium Hydroxide / Magnesium Stearate / Titanium Dioxide (Opaque Coating) Solubilizer / Diluent / PH Modifier / Light Shield (Engineered specifically utilizing Alkaline Matrix Solubilization. Telmisartan requires a highly alkaline environment to dissolve, while Cilnidipine is light-sensitive. Our bilayer technology ensures each API is released at its peak kinetic window). Lisinopril Tablet
FreeProduct Composition & Available Portfolio Range
We manufacture Lisinopril in exact, compendial strengths calibrated to support initial introductory titration up to high-potency cardioprotective maintenance blocks.
Active Ingredient Monograph Available Strengths Formulation Matrix Delivery System Primary Clinical Application Lisinopril Anhydrous / Dihydrate USP / BP / IP 5 mg Oral Solid Uncoated Tablet Initial Titration: For low-dose introductory management, pediatric hypertension, or initial combination therapy initiation. Lisinopril Anhydrous / Dihydrate USP / BP / IP 10 mg Oral Solid Uncoated Tablet Core Commercial Volume: Standard international baseline daily dose for mild-to-moderate chronic essential hypertension. Lisinopril Anhydrous / Dihydrate USP / BP / IP 20 mg Oral High-Potency Solid Tablet Advanced Cardioprotection: High-strength configuration calibrated for severe heart failure management and post-infarction survival optimization. Methyldopa Tablet
FreeProduct Composition & Available Strengths
We supply Methyldopa in standard, exact strengths designed to facilitate the careful, progressive dose titration required in gestational healthcare.
Active Ingredient Monograph Available Strengths Formulation Matrix Delivery System Primary Clinical Application Methyldopa Anhydrous IP / BP / USP 250 mg Oral Solid Film-Coated Tablet (Scored for micro-titration) Initial Titration / Baseline Care: For early-stage gestational hypertension and lower-dose fine-tuning. Methyldopa Anhydrous IP / BP / USP 500 mg Oral Solid Film-Coated Tablet (Engineered for uniform mass release) High-Potency Maintenance: For advanced chronic hypertension during pregnancy and severe pre-eclamptic stabilization. Nifedipine Tablet
FreeProduct Composition & Structural Formats
We supply Nifedipine in exact, internationally standardized strengths, optimized for immediate-release emergency titration or controlled-release daily maintenance.
Active Ingredient Available Strengths Formulation Mechanism Primary Clinical Target Nifedipine IP / BP / USP 10 mg Immediate or Modified Release Acute Titration / Tocolysis: For rapid blood pressure adjustment or suppression of premature labor. Nifedipine IP / BP / USP 20 mg Sustained / Retard Matrix Daily Maintenance: Continuous 12-to-24-hour plasma concentration for chronic hypertension and angina.
